- Home
- CCEC vs ETNB Comparison
CCEC vs ETNB Comparison
Compare CCEC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- ETNB
- Stock Information
- Founded
- CCEC 2007
- ETNB 2018
- Country
- CCEC Greece
- ETNB United States
- Employees
- CCEC N/A
- ETNB N/A
- Industry
- CCEC Marine Transportation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- ETNB Health Care
- Exchange
- CCEC Nasdaq
- ETNB Nasdaq
- Market Cap
- CCEC 1.1B
- ETNB 1.0B
- IPO Year
- CCEC 2007
- ETNB 2019
- Fundamental
- Price
- CCEC $17.00
- ETNB $6.06
- Analyst Decision
- CCEC Buy
- ETNB Strong Buy
- Analyst Count
- CCEC 2
- ETNB 10
- Target Price
- CCEC $24.00
- ETNB $27.56
- AVG Volume (30 Days)
- CCEC 16.5K
- ETNB 2.5M
- Earning Date
- CCEC 04-29-2025
- ETNB 05-08-2025
- Dividend Yield
- CCEC 3.53%
- ETNB N/A
- EPS Growth
- CCEC 20.78
- ETNB N/A
- EPS
- CCEC 2.60
- ETNB N/A
- Revenue
- CCEC $369,413,000.00
- ETNB N/A
- Revenue This Year
- CCEC $19.13
- ETNB N/A
- Revenue Next Year
- CCEC $20.93
- ETNB N/A
- P/E Ratio
- CCEC $139.82
- ETNB N/A
- Revenue Growth
- CCEC 2.45
- ETNB N/A
- 52 Week Low
- CCEC $14.09
- ETNB $4.16
- 52 Week High
- CCEC $20.40
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- ETNB 42.57
- Support Level
- CCEC N/A
- ETNB $5.68
- Resistance Level
- CCEC N/A
- ETNB $6.13
- Average True Range (ATR)
- CCEC 0.00
- ETNB 0.69
- MACD
- CCEC 0.00
- ETNB 0.03
- Stochastic Oscillator
- CCEC 0.00
- ETNB 51.62
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).